Altered Cell Modalities: Cancer Treatments and Nursing Management
Page 1: Altered Cell Modalities
Presenter: Dr. Vivek Agnihotri, DNP, APN, CCRN, Associate Professor
Page 2: Clinical Objectives
Differentiate cancer therapeutic modalities: surgery, radiation, chemotherapy, biologic therapies, and targeted agents.
Classify chemotherapeutic medications based on cell-cycle specificity and mechanism of action.
Distinguish delivery mechanisms and safety protocols between external beam teletherapy and internal brachytherapy.
Identify tissue toxicities, comprehensive nursing interventions, and nutritional support requirements for oncology patients.
Page 3: Goals of Cancer Therapy
Curative: Complete elimination and eradication of malignant disease.
Control: Slowing tumor progression, preventing cellular dissemination, and stabilizing disease burden.
Palliative: Relieving distressing symptoms, managing pain, and mitigating physical and psychosocial stress to promote comfort.
Page 4: Overview of Cancer Treatment Modalities
Surgical: Direct operative intervention to resect or debulk diseased tissue.
Radiation Therapy: Ionizing high-energy beams or isotope sources that damage targeted cellular DNA.
Chemotherapy: Pharmacologic agents that systemically destroy rapidly proliferating cells.
Biotherapy: Living organism-derived substances that alter biologic and immune responses against neoplastic cells.
Complementary & Alternative Medicine (CAM): Non-standard medical practices and products utilized alongside or outside conventional care.

Pages 5–7: Surgical Oncology Applications
Clinical Indications:
Primary treatment modality of choice for localized solid tumors.
Surgical failure occurs predominantly due to occult or undetected metastasis present at the time of diagnosis.
Roles Across Treatment Continuum:
Diagnosis & Staging: Tissue biopsy and anatomic mapping of tumor extension.
Primary Treatment: Definitive curative surgical resection.
Preventive Care: Prophylactic removal of non-vital, high-risk premalignant tissues.
Palliative Care: Relief of mechanical obstruction, pain reduction, and symptom control.
Reconstructive / Rehabilitative: Functional and cosmetic restoration following radical tissue excision.
Supportive Care: Placement of vascular access devices (e.g., ports) or enteral feeding routes.
Page 8: Perioperative Nursing Management
Preoperative Priorities: Thorough patient and family education; clinical management of procedural anxiety.
Postoperative Priorities: Systematic pain management and targeted complication prevention:
Respiratory Complications: Atelectasis and Pneumonia.
Cardiovascular & Wound Complications: Deep vein thrombosis (DVT) and surgical site infections (SSI).
Psychosocial support for altered body image and recovery stress.
Pages 9–11: Radiation Therapy Principles & Teletherapy
Definition: Utilization of targeted ionizing radiation or radioisotopes to induce irreversible lethal DNA double-strand breaks in malignant cells.
Teletherapy (External Beam Therapy):
Radiation is delivered from an external ionizing source outside the patient.
Permanent tattoo markings guide daily stereotactic positioning.
The patient and their body excreta are never radioactive.
Specialized techniques include Cyber knife Rx.

Pages 12–13: Brachytherapy & Radiation Protection Protocols
Brachytherapy Delivery Modalities:
Sealed Brachytherapy: Radioactive seeds or needles are implanted within or directly adjacent to the tumor bed. The patient actively emits radiation, but body excreta are non-radioactive.
Unsealed Brachytherapy: Radioactive isotopes are administered orally, intravenously, or via intracavitary instillation. Both the patient and all body fluids/excreta are radioactive.

Nursing and Radiation Safety Interventions:
Place patient in a private room with a dedicated private bathroom.
Healthcare workers must wear a personal Dosimeter badge at all times to monitor cumulative exposure.
Pregnant nursing personnel are strictly prohibited from caring for the patient.
Restrict patient visitors to a maximum duration of per visit and require them to maintain a minimum physical distance of .
Never handle dislodged radioactive implants with bare hands; use long-handled forceps to place items into a bedside lead container.
Pages 14–16: Radiation Complications & Skin Care Protocols
Site-Specific Adverse Effects:
Cutaneous desquamation and erythema.
Stomatitis and xerostomia (salivary gland dysfunction).
Localized alopecia, dysgeusia (altered taste), and profound fatigue.
Long-term tissue fibrosis, stricture, esophagitis, and hemorrhagic cystitis.

Patient Education for Irradiated Skin:
Wash the irradiated field gently using only tepid water and mild soap; pat dry rather than rubbing.
Use bare hands to clean the area instead of rough washcloths.
Avoid all unapproved powders, cosmetic lotions, ointments, and medicinal creams.
Protect irradiated tissue from direct heat sources and sunlight exposure.
Shave strictly with electric razors; wear loose, non-restrictive soft cotton garments.
Never scrub, rub off, or attempt to remove external skin tattoo markings.
Pages 17–22: Chemotherapy Administration, Dosing & Safe Handling
Mechanism: Destruction of rapidly dividing malignant cells by disrupting cellular DNA and interfering with cell division.
Routes of Administration: Oral, intravenous (IV), intra-arterial, intra-cavitary, and intra-thecal.

Clinical Dosing Considerations:
Dosing calculations are strictly individualized according to the patient’s Total Body Surface Area (TBSA).
The medical oncologist sets treatment cycles and intervals based on cumulative organ toxicity and the predicted bone marrow recovery Nadir.
Occupational Safety Protocols:
Reconstitute and manipulate hazardous drugs inside a certified Class II biological safety cabinet.
Wear specialized protective gowns and chemotherapy-tested gloves during all handling, administration, and disposal steps.
Use Luer-Lock connectors exclusively on all IV tubing sets.
Dispose of all contaminated administration sets, supplies, and patient excreta as hazardous cytotoxic waste.
Pages 23–29: Chemotherapy Classifications & Adjuvant Agents
Alkylating Agents (Cell Cycle Non-Specific):
Examples: Cyclophosphamide (Cytoxan), Cisplatin (Platinol), Busulfan (Myleran), Chlorambucil (Leukeran), Mechloretamine (nitrogen mustard).
Mechanism: Cross-links DNA strands to halt replication and transcription.
Key Toxicities: Myelosuppression (anemia, neutropenia, thrombocytopenia), nephrotoxicity, neurotoxicity, and hemorrhagic cystitis.
Antimetabolites (Cell Cycle Specific – S Phase):
Examples: Methotrexate, 5FU (5-fluorouracil), 6MP (6-mercaptopurine), Cytarbine (Cytosine arabinoside, ARA-C).
Mechanism: Mimics essential metabolic building blocks to inhibit DNA and RNA synthesis.
Key Toxicities: Severe bone marrow suppression, gastrointestinal distress, alopecia, rash, hepatic inflammation, and fatigue.
Anti-Tumor Antibiotics (Cell Cycle Non-Specific):
Examples: Doxorubicin (Adriamycin), Bleomycin (Blenoxane), Plicamycin (Mithramycin), Mitomycin (Mutamycin).
Mechanism: Intercalates within DNA base pairs, fracturing the helical strand.
Key Toxicities: Cardiotoxicity, pulmonary toxicity, hepatotoxicity, and myelosuppression.
Antimitotics (Cell Cycle Specific – M Phase):
Examples: Vincristine (Oncovin), Vinblastine (Velban), Paclitaxel (Taxol).
Mechanism: Disrupts mitotic spindle formation to inhibit cell division.
Key Toxicities: Severe vesicant potential, hypersensitivity reactions, and chemotherapy-induced peripheral neuropathy (CIPN).
Hormonal Agents:
Examples: Tamoxifen (Nolvadex), Evista (Raloxifene), Corticosteroids (Prednisone), Leuprolied (Lupron), Golserelin (Zoladex), Femara (Letrozole), Arimidex (Anastrozole), and specific sex steroids (androgens, estrogens, progesterone).
Topoisomerase Inhibitors (Cell Cycle Specific – S Phase):
Examples: Irinotecan, Topotecan.
Mechanism: Inhibits topoisomerase I enzymes responsible for relieving torsional tension, winding, and supercoiling during DNA replication.
Adjuvant & Supportive Pharmacotherapy:
Antiemetics: Zofran (ondansetron), Kytril (Granisetron), Anzemet (dolasetron).
Bone Protection: Pamindronate (Aredia).
Bladder Cytoprotection (against ifosfamide/cyclophosphamide urotoxicity): Mesna (mesnex).
Radioprotection / Chemoprotection: Amifostine (ethyol).
Cardioprotection (against anthracyclines): Doxruzoxane (zinecard).
Pages 30–32: General Toxicities & Standard Nursing Protocols
Major Systemic Toxicities:
Bone marrow suppression (pancytopenia), GI mucosal injury, alopecia, secondary carcinogenesis, reproductive gonadal toxicity, chemo-brain (cognitive dysfunction), and hyperuricemia secondary to rapid tumor lysis.
Standard Nursing Protocols for Administration:
Obtain detailed medical history, baseline allergy profile, height, weight, and signed informed consent.
Review baseline laboratory diagnostics (CBC, hepatic and renal panels).
Perform mandatory independent dual-verification of orders and drug calculations with a second chemotherapy-certified registered nurse.
Confirm blood return and verify intravenous patency before, during, and after vesicant infusion.
Pages 33–36: Nursing Care for Common Oncology Complications
Stomatitis / Mucositis:
Inspect oral mucosa and dentition on a daily schedule.
Cleanse with an ultra-soft toothbrush; do not floss.
Avoid alcohol-based commercial mouthwashes; utilize topical mucosal analgesics as prescribed.
Apply water-based lip and oral lubricants; eliminate tobacco, ethanol, hard candy, and thermal/spicy dietary irritants.
Absolute Neutropenia:
Place in a private room; assign healthcare workers to evaluate this patient first.
Perform rigorous hand hygiene using alcohol-based rubs before and after patient contact.
Enforce strict aseptic technique for all invasive vascular or catheter interventions.
Monitor daily CBC with differential; monitor vital signs including temperature.
Notify the healthcare provider immediately for any temperature elevation: .
Institute a low-bacteria diet (exclude all fresh, unwashed fruits, raw vegetables, and rare/partially cooked meats).
Prohibit standing water or bedside humidifiers; administer Filgrastim (Neupogen) as ordered.
Thrombocytopenia (Bleeding Risk):
Use soft toothbrushes and electric razors exclusively; handle and reposition gently.
Avoid invasive trauma: prohibit rectal temperatures, suppositories, and unnecessary IM/IV punctures.
Defer elective dental procedures while counts are depressed; monitor platelet values and inspect the skin for petechiae and ecchymosis.
Chemotherapy-Induced Peripheral Neuropathy (CIPN):
Wear closed-toed shoes with thick protective soles; complete daily visual foot inspections for lesions.
Protect extremities against thermal injury in cold weather; wear protective gloves when washing dishes or gardening.
Change postural positions slowly; eliminate loose throw rugs, clutter, and obstacles; utilize stair handrails.
Pages 37–42: Biotherapy, Targeted Therapies & Vaccines
Cytokines:
Interferons (Interferon alfa 2a, Interferon alfa 2b): Augment innate immune surveillance and cell-mediated toxicity.
Interleukins (Interleukin 2): Promote T-cell proliferation and immune activation.
Colony Stimulating Factors (Hematopoietic Growth Factors):
Erythropoietin (Epogen, Procrit): Stimulates erythrocyte (RBC) synthesis.
Filgrastim (Neupogen), Pegfilgrastim (Neulesta), Sargramostin (Granulocyte): Increase leukocyte and granulocyte counts (monitor patients for bone pain).
Tyrosine Kinase Inhibitors: Imatinib (Gleevec), Erlotinib (Tarceva), Crizotinib (Xalkori).
Monoclonal Antibodies (MAB):
Trastuzumab (Herceptin): Targets HER2 receptor overexpression in specific breast cancers.
Rituximab (Rituxan): Targets CD20 in non-Hodgkin's Lymphoma (NHL).
Cetuximab (Erbitux): Targets EGFR in metastatic colorectal cancer (CRC).
Bevacizumab (Avastin): Anti-VEGF antibody that inhibits tumor angiogenesis in metastatic CRC.
Cancer Vaccines:
Utilized primarily for active therapy rather than prophylactic disease prevention.
FDA-Approved Agents: Sipuleucel-T (Provenge®) for refractory prostate cancer; BCG intravesical vaccine for superficial bladder cancer; Oncovax for colorectal malignancies.

Pages 43–44: Complementary and Alternative Medicine (CAM)
Epidemiology: Over is spent annually by Americans on CAM, with of cancer patients incorporating non-traditional practices.
Clinical Considerations:
Patients must be cautioned against delaying, discontinuing, or substituting unproven therapies in place of standard curative regimens.
Exercise extreme caution regarding unrealistic curative guarantees or unscientific claims.
Natural substances must not be assumed safe or physiologically inert, as herbals and supplements frequently interact with conventional chemotherapeutic agents.